RUSSIAN AUTHORITIES PLAN TO CURTAIL MONOPOLIES OF PHARMA COMPANIES BY BANNING OR RESTRICTING THE SUBSEQUENT PATENTING OF DIFFERENT FORMS OF KNOWN MEDICAL SUBSTANCES

It is well known that pharmaceutical companies tend to use all lawful opportunities to extend the term of protection of patented medical substances, and in that way sometimes delay generics market entry. One option is an extension of the patent term, which is available to counterbalance regulatory delays occurring in the marketing authorization issuance…

Scarica l’articolo